117 related articles for article (PubMed ID: 21787288)
21. Discovery of an 8-aza-5-thiaProstaglandin E1 analog as a highly selective EP4 receptor agonist.
Kambe T; Maruyama T; Naganawa A; Asada M; Seki A; Maruyama T; Nakai H; Toda M
Chem Pharm Bull (Tokyo); 2011; 59(12):1494-508. PubMed ID: 22130372
[TBL] [Abstract][Full Text] [Related]
22. The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype.
Weinreb M; Grosskopf A; Shir N
Am J Physiol; 1999 Feb; 276(2):E376-83. PubMed ID: 9950799
[TBL] [Abstract][Full Text] [Related]
23. Structural features of subtype-selective EP receptor modulators.
Markovič T; Jakopin Ž; Dolenc MS; Mlinarič-Raščan I
Drug Discov Today; 2017 Jan; 22(1):57-71. PubMed ID: 27506873
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: involvement of protein kinase C-θ activation.
Takahashi T; Uehara H; Ogawa H; Umemoto H; Bando Y; Izumi K
Oncotarget; 2015 Mar; 6(7):4829-44. PubMed ID: 25638159
[TBL] [Abstract][Full Text] [Related]
25. Novel high-throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors.
Sieber P; Schäfer A; Lieberherr R; Le Goff F; Stritt M; Welford RWD; Gatfield J; Peter O; Nayler O; Lüthi U
PLoS One; 2018; 13(11):e0207872. PubMed ID: 30485339
[TBL] [Abstract][Full Text] [Related]
26. Discovery of highly potent dual EP(2) and EP(3) agonists with subtype selectivity.
Kinoshita A; Higashino M; Aratani Y; Kakuuchi A; Matsuya H; Ohmoto K
Bioorg Med Chem Lett; 2016 Feb; 26(3):1016-1019. PubMed ID: 26725951
[TBL] [Abstract][Full Text] [Related]
27. The Gαs-protein-mediated pathway may be steadily stimulated by prostanoid EP2 receptors, but not by EP4 receptors.
Fukushima K; Senoo K; Kurata N; Regan JW; Fujino H
FEBS Open Bio; 2022 Apr; 12(4):775-783. PubMed ID: 35124898
[TBL] [Abstract][Full Text] [Related]
28. Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor.
Säfholm J; Manson ML; Bood J; Delin I; Orre AC; Bergman P; Al-Ameri M; Dahlén SE; Adner M
J Allergy Clin Immunol; 2015 Nov; 136(5):1232-9.e1. PubMed ID: 25962903
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of the S1P
Filipenko I; Schwalm S; Reali L; Pfeilschifter J; Fabbro D; Huwiler A; Zangemeister-Wittke U
Biochim Biophys Acta; 2016 Nov; 1861(11):1840-1851. PubMed ID: 27616330
[TBL] [Abstract][Full Text] [Related]
30. Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines.
Okuyama T; Ishihara S; Sato H; Rumi MA; Kawashima K; Miyaoka Y; Suetsugu H; Kazumori H; Cava CF; Kadowaki Y; Fukuda R; Kinoshita Y
J Lab Clin Med; 2002 Aug; 140(2):92-102. PubMed ID: 12228765
[TBL] [Abstract][Full Text] [Related]
31. [Cooperation of two subtypes of PGE2 receptor, Gi coupled EP3 and Gs coupled EP2 or EP4 subtype].
Hatae N
Yakugaku Zasshi; 2003 Oct; 123(10):837-43. PubMed ID: 14577329
[TBL] [Abstract][Full Text] [Related]
32. Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure.
Vukicevic S; Simic P; Borovecki F; Grgurevic L; Rogic D; Orlic I; Grasser WA; Thompson DD; Paralkar VM
Kidney Int; 2006 Sep; 70(6):1099-106. PubMed ID: 16871242
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of lysyl oxidase by prostaglandin E2 via EP2/EP4 receptors in human amnion fibroblasts: Implications for parturition.
Liu C; Zhu P; Wang W; Li W; Shu Q; Chen ZJ; Myatt L; Sun K
Mol Cell Endocrinol; 2016 Mar; 424():118-27. PubMed ID: 26826430
[TBL] [Abstract][Full Text] [Related]
34. Prostaglandin E2 promotes human CD34+ cells homing through EP2 and EP4 in vitro.
Wang Y; Lai S; Tang J; Feng C; Liu F; Su C; Zou W; Chen H; Xu D
Mol Med Rep; 2017 Jul; 16(1):639-646. PubMed ID: 28560401
[TBL] [Abstract][Full Text] [Related]
35. Prostaglandin E(2) receptors in bone formation.
Li M; Thompson DD; Paralkar VM
Int Orthop; 2007 Dec; 31(6):767-72. PubMed ID: 17593365
[TBL] [Abstract][Full Text] [Related]
36. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs.
Suzawa T; Miyaura C; Inada M; Maruyama T; Sugimoto Y; Ushikubi F; Ichikawa A; Narumiya S; Suda T
Endocrinology; 2000 Apr; 141(4):1554-9. PubMed ID: 10746663
[TBL] [Abstract][Full Text] [Related]
37. Up-regulation of prostaglandin E receptor EP2 and EP4 subtypes in rat synovial tissues with adjuvant arthritis.
Kurihara Y; Endo H; Akahoshi T; Kondo H
Clin Exp Immunol; 2001 Feb; 123(2):323-30. PubMed ID: 11207665
[TBL] [Abstract][Full Text] [Related]
38. Regulation of nerve growth factor by anti-inflammatory drugs, a steroid, and a selective cyclooxygenase 2 inhibitor in human intervertebral disc cells stimulated with interleukin-1.
Alimasi W; Sawaji Y; Endo K; Yorifuji M; Suzuki H; Kosaka T; Shishido T; Yamamoto K
Spine (Phila Pa 1976); 2013 Aug; 38(17):1466-72. PubMed ID: 23574818
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of γ-lactam analogs of PGE₂ as EP4 and EP2/EP4 agonists.
Kambe T; Maruyama T; Nakai Y; Oida H; Maruyama T; Abe N; Nishiura A; Nakai H; Toda M
Bioorg Med Chem; 2012 Jun; 20(11):3502-22. PubMed ID: 22546206
[TBL] [Abstract][Full Text] [Related]
40. Role of prostaglandin E receptor subtypes EP2 and EP4 in autocrine and paracrine functions of vascular endothelial growth factor in the inner ear.
Hori R; Nakagawa T; Yamamoto N; Hamaguchi K; Ito J
BMC Neurosci; 2010 Mar; 11():35. PubMed ID: 20219142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
